London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There’s a ST Tropez on boohoo site would that be the same person, I’m guessing yes? New to this so not sure. But guessing you can’t have the same name as someone else.
What a carnage of a day! I’ve gone half and half not lost yet but hindsight is not helpful now. Just gonna sit tight and be patient. Feel a bit mugged by mms. But I’m gonna dig in. I think this will move up as even into the next trials the extra tight safety protocols as I understand from RNS have been tested so I don’t be believe further trials will be as long as previous.
Wow glad I sold half last week!
I am loss making on the remainder now, but not too worried
In terms of volume this is on par with many days last week and like many days last week buyers and sellers in pretty equal. value.
The only concern for me is the value of the transactions i.e. are the big boys selling large and the buys coming from a swarm if little punters averaging down.
More angry with the likes of saint-tropez who I hope will have the good sence not to post here for a while. Although I was not taken in by his nonsence I get very angry at the thought that others might have been.
Looking forward to a better tomorrow.
Lunatic
You idiot you did miss out on the big increase 2 weeks ago
noticed the trolls are out in force where were they last week lol this will go back up
It was good while it lasted a bit too good to be true ! I'm glad i got out 2 weeks ago thinking i'd missed out on that big rise how lucky i was ,Sorry lads
Ignore the circus of derampers !!
£2m is nothing.. that is the problem Also results were not good enough
Full of trolls but they all disappear when the share price goes up. That hopsta999 is the funniest. 2p placing lmao. Then the shares went up 1700%.
And he missed out.
soon 20p then 15p then 10p!
25p buy......? Puke emoji
The wise are buying.
Thanks
so if they are not taking it to the next trial .......
what is the point of VAL ........ ?
they had this "Big RNS " back in Dec 2018 claiming all sorts ....
Mon, 10th Dec 2018 07:00
RNS Number : 8910J
ValiRx PLC
09 December 2018
VALIRX PLC
("ValiRx" or the "Company")
UPDATE ON VAL201 CLINICAL TRIAL
"Positive Effect on Cancer Patients"
"Evidence revealed of decrease in prostate cancer biomarker PSA, related to dosing with VAL201"
London, UK., 10 December 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is proud to announce that independent analysis of VAL201 data shows a statistically significant dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.
This represents an initial formal statistical analysis of the VAL201 clinical data conducted by Dr Wilson Caparrós-Wanderley, an independent statistical consultant. This was undertaken using a non-parametric approach - both the well-established 'Friedman Test' (developed by M. Friedman in 1937) and the most up-to-date statistical method, 'Repeated Measures Multiple Correlation Analysis' (refined by Bakdash and Marusich in 2017).
This analysis reveals that volunteers treated with VAL201 display a statistically significant correlation for reductions over time in the amount of Testosterone and Prostate Specific Antigen ("PSA"), both of which are commonly-used markers for disease progression in prostate cancer.
The data further confirms that VAL201 has no statistically significant adverse trends across liver or kidney function. Furthermore, with no impact on cardiac rhythm in the patients either, this data further reinforces the continuation of the good safety and tolerability data emerging from the trial.
In addition to the independent analysis, the pharmacokinetics information collected from the clinical evaluation of ValiRx's more recent patients, shows that ValiRx is addressing the protocol's primary and secondary endpoints - as well as all the exploratory tertiary end points.
Further information about the endpoints is to be found posted on the NIH website, www.ClinicalTrials.gov, under: 'Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)'.
Dr Satu Vainikka, CEO of ValiRx, commented: "I am delighted to receive this analysis from an external expert, showing that VAL201 is having a positive and desired effect on prostate cancer patients' disease markers. Effectively, the more a patient takes VAL201, the more a patient's PSA will decrease".
"This is fantastic news and it heralds our entry into the pivotal stage of VAL201's clinical trial programme. I thank the team for their hard work in delivering these very encouraging and positive outcomes".
Sold at 40 will jump back in when they bottom out
@teamhanz. Totally agree
This actually doesn't make sense. We have cash in the bank, their plan isn't go into later stage trials as clearly mapped out...This is MM manipulation to the greatest extent i have seen. This will go the other way and MMs have literally played a blinder today. Watch this space!!! we will be back to where we were in no time. Mark my words!
over 30 to sell now.
MM dropped this for nowt!
Took some 29p. Thank me later lol
did warn you all weeks ago! be very careful putting money in here! my 98% loss dropped to 85%! on it's way back into the 90's now
29 to sell...ride it up
strong close and gap up on open!
report to fca
It's gone from the top of the risers leader board to the top of the fallers leader board on the same day... on the good news of a potential cancer treatment. Quite unbelievable.
This drop is beyond belief. A great RNS and this happens. Could really do with some postives from Dr. Dilly. Can't believe she would expect see the sp get slaughtered like it has today. Completely unjustified. Confidence crushed in a few hours. Really need some damage limitation from the BOD.